Clinical Trial Update: Cadonilimab (AK104) in the Treatment of Nasopharyngeal Carcinoma [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update for Cadonilimab (AK104) in nasopharyngeal carcinoma; status not reported in the provided snippet.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Nasopharyngeal Carcinoma

Drugs mentioned

• Cadonilimab

Snippet

Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Conditions: Nasopharyngeal Carcinoma | Phase 2 | Status: UNKNOWN